Singapore markets closed
Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,947.95 -927.86 (-1.43%) CMC Crypto 200
1,383.71 -12.82 (-0.92%)
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 202.46 |
| Open | 201.22 |
| Bid | 208.77 x 400 |
| Ask | 209.35 x 300 |
| Day's range | 199.10 - 210.82 |
| 52-week range | 189.44 - 319.76 |
| Volume | |
| Avg. volume | 1,260,329 |
| Market cap | 30.415B |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 26.11 |
| EPS (TTM) | 8.00 |
| Earnings date | 23 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 286.10 |
ZacksSage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
GuruFocus.comDecoding Biogen Inc (BIIB): A Strategic SWOT Insight
Insightful Analysis of Biogen Inc's Financials and Strategic Positioning
© 2024 Yahoo. All rights reserved.